Form 4: NovaBay Director Lazar Exits Major Stake

David E. Lazar, a Director and 10% owner of NovaBay Pharmaceuticals, Inc., reported the conversion of preferred stock and a significant divestment of his holdings, marking an exit filing.

Summary

• David E. Lazar, a Director and 10% owner of NovaBay Pharmaceuticals, Inc. (NBY), filed a Form 4 indicating changes in his beneficial ownership.
• The filing constitutes an "exit filing" for Mr. Lazar, signifying he is no longer subject to Section 16 reporting obligations.
• On October 21, 2025, 39,925 shares of Series D Convertible Preferred Stock automatically converted into 6,388,000 shares of Common Stock.
• This conversion occurred three business days after the company's Annual Meeting on October 16, 2025.
• Each share of Series D Preferred Stock is convertible into 160 shares of Common Stock.
• Prior to this conversion, on October 9, 2025, Mr. Lazar entered into a Securities Purchase Agreement.
• Under this agreement, he sold 441,325 shares of Series D Preferred Stock for $9,850,000.
• He also sold rights and obligations to purchase 268,750 shares of Series E Preferred Stock for an additional $2,150,000, which was payable to the Issuer.
• The closing of this October Transaction occurred on October 16, 2025, following the Issuer's Annual Meeting.
• Following the October Transaction, Mr. Lazar retained the 39,925 shares of Series D Preferred Stock that subsequently converted.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal due to a significant insider (Director and 10% owner) divesting a substantial portion of their holdings and filing an exit report, which often indicates a lack of confidence in future performance.

Positives

• NovaBay Pharmaceuticals, Inc. received $2,150,000 from the sale of rights to purchase Series E Preferred Stock, representing a capital inflow to the company.

Negatives

• A Director and 10% owner, David E. Lazar, has significantly reduced his stake in NovaBay Pharmaceuticals, Inc. and filed an "exit filing," which can be interpreted as a lack of confidence.
• The divestment of 441,325 shares of Series D Preferred Stock for $9,850,000 by a major insider could signal a strategic move away from the company's future prospects.

Risks

• The significant reduction in ownership by a Director and 10% owner could be perceived negatively by the market, potentially impacting investor confidence and the company's share price.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from NovaBay Pharmaceuticals, Inc. It primarily details a past transaction by a reporting person.

Industry Context

StockSavvy.ai notes that insider selling, especially by a significant shareholder and director, can sometimes precede periods of underperformance or reflect a lack of confidence in the company's near-term prospects. This divestment by a 10% owner and Director of NovaBay Pharmaceuticals, Inc. could be interpreted by the market as a strategic move by the insider to reallocate capital, potentially signaling a perceived plateau or decline in the company's growth trajectory relative to other investment opportunities.

Management Changes

Related Party Transactions

• David E. Lazar, a Director and 10% owner, sold 441,325 shares of Series D Preferred Stock for $9,850,000 and rights to purchase 268,750 shares of Series E Preferred Stock for $2,150,000 (payable to the Issuer) via a Securities Purchase Agreement.

Stakeholder Impact

• Shareholders: May experience decreased confidence due to a major insider's significant divestment, potentially leading to downward pressure on the stock price.
• Company (NovaBay Pharmaceuticals, Inc.): Received $2,150,000 from the sale of Series E Preferred Stock rights, providing additional capital.

Next Steps

• The reporting person is no longer subject to Section 16 reporting requirements, as this is an "exit filing."

Key Dates

Recommendation

The significant divestment by a Director and 10% owner, David E. Lazar, coupled with the 'exit filing' status, suggests a lack of long-term conviction from a key insider. This action typically signals potential headwinds or a belief that the stock's upside is limited, prompting a seasoned investor to consider reducing or exiting their position.

Keywords

NovaBay Pharmaceuticals, NBY, SEC Form 4, Insider Trading, Stock Conversion, Preferred Stock, Common Stock, David E. Lazar, Director, 10% Owner, Divestment, Exit Filing